Rotor termination is critically dependent on kinetic properties of I Kur inhibitors in an In Silico model of chronic atrial fibrillation

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Scholz, Eberhard P ^a   Carrillo Bustamante, Paola ^c   Fischer, Fathima ^a   Wilhelms, Mathias ^b   Zitron, Edgar ^a,d   Dössel, Olaf ^b   Katus, Hugo A ^a,d   Seemann, Gunnar ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c UTRECHT UNIVERSITY   (Netherlands)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL BLOCKING AGENT; ULTRA RAPID DELAYED RECTIFIER POTASSIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; ELECTRIC POTENTIAL; HEART ATRIUM FIBRILLATION; MATHEMATICAL MODEL;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COMPUTER SIMULATION; DELAYED RECTIFIER POTASSIUM CHANNELS; ELECTROCARDIOGRAPHY; HEART ATRIA; HUMANS; KINETICS; MODELS, BIOLOGICAL; MYOCYTES, CARDIAC; POTASSIUM CHANNEL BLOCKERS;

EID: 84893361030     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083179     Document Type: Article

References (37)

1. Dobrev D, Nattel S (2010) New antiarrhythmic drugs for treatment of atrial fibrillation. The Lancet 375: 1212-1223. doi:10.1016/S0140-6736(10)60096- 7.
2. Ehrlich JR, Biliczki P, Hohnloser SH, Nattel S (2008) Atrial-selective approaches for the treatment of atrial fibrillation. Journal of the American College of Cardiology 51: 787-792. doi:10.1016/j.jacc.2007.08.067. (Pubitemid 351253743)
3. Nattel S (2002) New ideas about atrial fibrillation 50 years on. Nature 415: 219-226. doi:10.1038/415219a.
4. Nattel S, Carlsson L (2006) Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 5: 1034-1049. doi:10.1038/nrd2112. (Pubitemid 44835130)
5. Nattel S, Yue L, Wang Z (1999) Cardiac ultrarapid delayed rectifiers: a novel potassium current family o f functional similarity and molecular diversity. Cell Physiol Biochem 9: 217-226.
6. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 110: 2299-2306. doi:10.1161/01.CIR.0000145155.60288.71.
7. Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, et al. (2006) Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 15: 2185-2191. doi:10.1093/hmg/ddl143. (Pubitemid 43985509)
8. Blass BE, Fensome A, Trybulski E, Magolda R, Gardell SJ, et al. (2009) Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4- methoxyphenyl) ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia. J Med Chem 52: 6531-6534. doi:10.1021/jm901042m.
9. Burashnikov A, Antzelevitch C (2003) Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation 107: 2355-2360. doi:10.1161/01.CIR.0000065578.00869.7C. (Pubitemid 36578508)
10. Kur promote atrial fibrillation? Heart Rhythm 5: 1304-1309. doi:10.1016/j.hrthm. 2008.05.020.
11. Regan CP, Stump GL, Wallace AA, Anderson KD, McIntyre CJ, et al. (2007) In vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-1, in rat, dog, and nonhuman primate. J Cardiovasc Pharmacol 49: 236-245. doi:10.1097/FJC.0b013e3180325b2a. (Pubitemid 46626016)
12. Regan CP, Wallace AA, Cresswell HK, Atkins CL, Lynch JJ (2006) In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate. J Pharmacol Exp Ther 316: 727-732. doi:10.1124/jpet.105. 094839. (Pubitemid 43131000)
13. Stump GL, Wallace AA, Regan CP, Lynch JJ (2005) In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther 315: 1362-1367. doi:10.1124/jpet.105.092197. (Pubitemid 41635426)
14. Tsujimae K, Murakami S, Kurachi Y (2008) In silico study on the effects of IKur block kinetics on prolongation of human action potential after atrial fibrillationinduced electrical remodeling. AJP: Heart and Circulatory Physiology 294: H793-H800. doi:10.1152/ajpheart.01229.2007. (Pubitemid 351253290)
15. Courtemanche M, Ramirez RJ, Nattel S (1999) Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res 42: 477-489. (Pubitemid 29243173)
16. Nattel S, Burstein B, Dobrev D (2008) Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 1: 62-73. doi:10.1161/CIRCEP.107.754564.
17. Seemann G, Bustamante PC, Ponto S, Wilhelms M, Scholz EP, et al. (2010) Atrial fibrillation-based electrical remodeling in a computer model of the human atrium. Computing in Cardiology 37: 417-420.
18. Seemann G, Sachse FB, Karl M, Weiss DL, Heuveline V, et al. (2010) Framework for Modular, Flexible and Efficient Solving the Cardiac Bidomain Equations Using PETSc. Progress in Industrial Mathematics at ECMI 2008. Mathematics in Industry. Berlin, Heidelberg: Springer Berlin Heidelberg, Vol. 15. pp. 363-369. doi:10.1007/978-3-642-12110-4-55.
19. Wilhelms M, Hettmann H, Maleckar MM, Koivumäki JT, Dössel O, et al. (2012) Benchmarking electrophysiological models of human atrial myocytes. Front Physiol 3: 487. doi:10.3389/fphys.2012.00487.
20. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, et al. (1999) Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 44: 121-131. (Pubitemid 29431690)
21. van der Velden HM, Ausma J, Rook MB, Hellemons AJ, van Veen TA, et al. (2000) Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 46: 476-486. (Pubitemid 30319333)
22. Lagrutta A (2006) Novel, Potent Inhibitors of Human Kv1.5 K+ Channels and Ultrarapidly Activating Delayed Rectifier Potassium Current. Journal of Pharmacology and Experimental Therapeutics 317: 1054-1063. doi:10.1124/jpet.106. 101162.
23. Pandit SV, Berenfeld O, Anumonwo JMB, Zaritski RM, Kneller J, et al. (2005) Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys J 88: 3806-3821. doi:10.1529/biophysj.105.060459. (Pubitemid 40991096)
24. Fenton FH, Cherry EM, Hastings HM, Evans SJ (2002) Multiple mechanisms of spiral wave breakup in a model of cardiac electrical activity. Chaos 12: 852-892. doi:10.1063/1.1504242.
25. Cherry EM, Fenton FH (2008) Visualization of spiral and scroll waves in simulated and experimental cardiac tissue. New J Phys 10: 125016. doi:10.1088/1367-2630/10/12/125016.
26. Kneller J, Zou R, Vigmond EJ, Wang Z, Leon LJ, et al. (2002) Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. Circulation Research 90: E73-E87. doi:10.1161/01.RES.0000019783.88094.BA.
27. Aslanidi OV, Colman MA, Stott J, Dobrzynski H, Boyett MR, et al. (2011) 3D virtual human atria: A computational platform for studying clinical atrial fibrillation. Progress in Biophysics and Molecular Biology 107: 156-168. doi:10.1016/j.pbiomolbio.2011.06.011.
28. Tobón C, Ruiz-Villa CA, Heidenreich E, Romero L, Hornero F, et al. (2013) A Three-Dimensional Human Atrial Model with Fiber Orientation. Electrograms and Arrhythmic Activation Patterns Relationship. PLoS ONE 8: e50883. doi:10.1371/journal.pone.0050883.s004.
29. Ng J, Kadish AH, Goldberger JJ (2006) Effect of electrogram characteristics on the relationship of dominant frequency to atrial activation rate in atrial fibrillation. Heart Rhythm 3: 1295-1305. doi:10.1016/j.hrthm. 2006.07.027. (Pubitemid 44615669)
30. Kneller J, Kalifa J, Zou R, Zaitsev AV, Warren M, et al. (2005) Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionicallyrealistic mathematical model. Circulation Research 96: e35-e47. doi:10.1161/01.RES.0000160709.49633.2b.
31. Raitt MH, Kusumoto W, Giraud GD, McAnulty JH (2004) Electrophysiologic predictors of the recurrence of persistent atrial fibrillation within 30 days of cardioversion. Am J Cardiol 93: 107-110. (Pubitemid 38022048)
32. Jacquemet V, Virag N, Kappenberger L (2005) Wavelength and vulnerability to atrial fibrillation: Insights from a computer model of human atria. Europace 7 Suppl 2: 83-92. doi:10.1016/j.eupc.2005.03.017.
33. Blaauw Y, Gögelein H, Tieleman RG, van Hunnik A, Schotten U, et al. (2004) "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 110: 1717-1724. doi:10.1161/01.CIR.0000143050.22291.2E.
34. Eckstein J, Maesen B, Linz D, Zeemering S, van Hunnik A, et al. (2011) Time course and mechanisms of endo-epicardial electrical dissociation during atrial fibrillation in the goat. Cardiovasc Res 89: 816-824. doi:10.1093/cvr/cvq336.
35. Verheule S, Tuyls E, Gharaviri A, Hulsmans S, van Hunnik A, et al. (2013) Loss of continuity in the thin epicardial layer because of endomysial fibrosis increases the complexity of atrial fibrillatory conduction. Circ Arrhythm Electrophysiol 6: 202-211. doi:10.1161/CIRCEP.112.975144.
36. Yamazaki M, Mironov S, Taravant C, Brec J, Vaquero LM, et al. (2012) Heterogeneous atrial wall thickness and stretch promote scroll waves anchoring during atrial fibrillation. Cardiovasc Res 94: 48-57. doi:10.1093/cvr/cvr357.
37. Hocini M (2002) Electrical Conduction in Canine Pulmonary Veins: Electrophysiological and Anatomic Correlation. Circulation 105: 2442-2448. doi:10.1161/01.CIR.0000016062.80020.11.